Up to 304 Additional QS-B220s Sold to French Airports as Implant Sciences Deepens its Foothold in EU
- QS-B220s sold across 17 airports in France is the latest in a series of European wins
Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has signed a contract for up to 304 of its QS-B220 desktop explosives trace detectors across 17 regional airports in France. The first 106 units are committed to being delivered over the next several months. Additional units are expected to be delivered through fiscal year 2016 and 2017. The sale was made through the Company's in-country, full-service distributor, Hi-Tech Detection Systems (HTDS).
"The fact that our QS-B220 had STAC certification prior to the creation ECAC standards gave us additional insight into the French aviation market. Our systems are highly regarded in the region, and we believe that procurement agents look to the QS-B220's value and performance and view the choice of selecting our unit as a 'smart' decision," said Dr. Darryl Jones, Implant Sciences' Vice President of Global Sales and Marketing. "We are very proud of the fact that this is the second major victory for us in France."
Military Airborne Intelligence, Surveillance & Reconnaissance (ISR) Technologies Market 2016-2026
"HTDS is an excellent long-term partner in France. Their ability to provide superior in-country support, such as service and training, makes them a strong ally and value-add for Implant Sciences. Their sound customer support capabilities also proved to be a deciding factor for this procurement," stated Richard Nelson, Implant Sciences' General Manager, EMEA.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source : Implant Sciences Corporation - view original press release
Mar 29 - 30, 2017 - London, United Kingdom
Apr 5 - 6, 2017 - London, United Kingdom
Mar 28 - 29, 2017 - Scottsdale, United States